This book explores the key factors which drive compliance and the part that healthcare professionals can play in improving this, with the goal of improving public health in its broadest sense
Vast global resources are ploughed into the delivery of treatment interventions ranging from diet and lifestyle advice through to complex surgery.
In all cases, whatever the intervention, unless the recipient is engaged with the process and understands why the intervention has been offered and the part they play in its success, compliance is an issue.
Even where the individual does engage and understand, he or she may choose not to comply.
Non-compliance is estimated to cost the pharma industry US $70 billion per year.
No figures exist for the cost to healthcare insurers and public health but non-compliance is undoubtedly one of the top five issues facing both drug developers and healthcare providers.
During clinical trials, non-compliance undermines the accuracy of the data generated from the whole trial as well as particular aspects such as the efficacy of different dosages.
This book explores the key factors which drive compliance and the part that healthcare professionals can play in improving this, with the key underlying goal of improving public health in its broadest sense.
About the editors, Madhu Davies and Faiz Kermani.
Madhu Davies is a consultant in pharmaceutical medicine, and editor of Pharmaceutical Physician journal.
She joined the pharmaceutical industry in 1993 following several years' clinical experience.
Faiz Kermani has several years experience in both academia and the pharmaceutical industry.
He has worked in pharmaceutical R+D, pricing and reimbursement, marketing and medical education.
He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a first class honours degree in pharmacology with toxicology from King's College, London.
He has written extensively on international healthcare issues, and is on the editorial board of a number of publications.
In March 2006, he was a delegate on the UK government's Trade and Investment Biotech Scoping mission to China and contributed to the subsequent report.
Contents.
List of contributors; Preface.
Part I What is Compliance?: Patient compliance - setting the scene, Dr Faiz Kermani and Dr Madhu Davies; View from the real world, Dr John Parkinson, Dr Li Wei and Professor TM MacDonald; Health economic aspects of patient non-compliance, Dr Dyffrig Hughes.
Part II The Challenge of Compliance: Patient compliance in the prevention and treatment of cardiovascular disease, Professor Gregory Peterson and Dr Shane Jackson; Patient compliance: A French perspective, Catherine Narayan-Dubois.
Part III Building For Success: Building in compliance from the start, Janice MacLennan; Formulating for compliance success, Dr Akira Kusai; Sweetening the pill - compliance and clinical trials, Dr Graham Wylie, Mike Bradburn, Dr Brian Edwards, Tanwen Evans and Dr Richard Kay; The role of pharma's field-based professionals in patient compliance, Dr Jane Chin; The use of interactive communications technology in disease management and compliance / persistence programmes, Dr Bill Byrom and David Stein; Patient compliance: Putting interventions into practice, Alan Blaskett.
Part IV Achieving Compliance: Looking To The Future: No quick fix: Shared decision making and tailored patient support as the route to more effective medicine taking, Caroline Kelham, Joanne Shaw and Geraldine Mynor; The role of the expert patient in compliance and concordance; Brendan O'Rourke; Patient compliance - a complex picture emerges, Dr Faiz Kermani; Index.
Patient Compliance (978-0-566-08658-8) edited by Madhu Davies and Faiz Kermani has just been published by Gower.
It is available in A4 Hardback priced at £85.00.
